Ceftolozane-tazobactam versus levofloxacin in urinary tract infection

被引：5
|
作者：
Popa, Ciprian [1 ]
Mircheva, Miryana [1 ]
Kraemer, Bernhard K. [1 ]
Berghofen, Andrea [1 ]
Krueger, Bernd [1 ]
机构：
[1] Heidelberg Univ, Univ Med Mannheim, D-68167 Mannheim, BW, Germany
来源：
LANCET | 2015年 / 386卷 / 10000期
关键词：
D O I：
10.1016/S0140-6736(15)00262-7
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1241 / 1242
页数：2
相关论文
共 50 条
  • [41] Ceftolozane-Tazobactam Population Pharmacokinetics and Dose Selection for Further Clinical Evaluation in Pediatric Patients with Complicated Urinary Tract or Complicated lntra-abdominal Infections
    Larson, Kajal B.
    Patel, Yogesh T.
    Willavize, Susan
    Bradley, John S.
    Rhee, Elizabeth G.
    Caro, Luzelena
    Rizk, Matthew L.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2019, 63 (06)
  • [42] Pharmacokinetics of Ceftolozane-Tazobactam during Prolonged Intermittent Renal Replacement Therapy
    Rawlins, Matthew
    Cheng, Vesa
    Raby, Edward
    Dyer, John
    Regli, Adrian
    Ingram, Paul
    McWhinney, Brett C.
    Ungerer, Jacobus P. J.
    Roberts, Jason A.
    CHEMOTHERAPY, 2018, 63 (04) : 203 - 206
  • [43] CEFTOLOZANE-TAZOBACTAM EX VIVO PHARMACOKINETICS IN AN EXTRACORPOREAL MEMBRANE OXYGENATION CIRCUIT
    Cies, Jeffrey
    Moore, Wayne
    Gilliam, Nadju
    Enache, Adela
    Chopra, Arun
    CRITICAL CARE MEDICINE, 2018, 46 (01) : 423 - 423
  • [44] Ceftolozane-Tazobactam Activity against Phylogenetically Diverse Clostridium difficile Strains
    Gonzalez, Mark D.
    Wallace, Meghan A.
    Hink, Tiffany
    Dubberke, Erik R.
    Burnham, Carey-Ann D.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (11) : 7084 - 7085
  • [45] CEFTOLOZANE-TAZOBACTAM PHARMACOKINETICS IN A PATIENT ON CONTINUOUS VENO-VENOUS HEMOFILTRATION
    Oliver, Wesley
    Gonzales, Jeffrey
    Heil, Emily
    Mehrotra, Shailly
    Robinett, Kathryn
    Saleeb, Paul
    Nicolau, David
    CRITICAL CARE MEDICINE, 2015, 43 (12)
  • [46] Nephrotoxicity of Vancomycin in Combination With Beta-Lactam Agents: Ceftolozane-Tazobactam vs Piperacillin-Tazobactam
    Alosaimy, Sara
    Lagnf, Abdalhamid M.
    Hobbs, Athena L., V
    Mubarez, Musa
    Kufel, Wesley D.
    Morrisette, Taylor
    Polisetty, Radhika S.
    Li, David
    Veve, Michael P.
    Simon, Sam P.
    Truong, James
    Finch, Natalie
    Venugopalan, Veena
    Rico, Matthew
    Amaya, Lee
    Yost, Christine
    Cubillos, Ashley
    Chandler, Elisabeth
    Patch, Megan
    Smith, Ian Murphy Kelsey
    Biagi, Mark
    Wrin, Justin
    Moore, W. Justin
    Molina, Kyle C.
    Rebold, Nicholas
    Holger, Dana
    Coyne, Ashlan J. Kunz
    Jorgensen, Sarah
    Witucki, Paige
    Tran, Nikki N.
    Davis, Susan L.
    Sakoulas, George
    Rybak, Michael J.
    CLINICAL INFECTIOUS DISEASES, 2023, 76 (03) : E1444 - E1455
  • [47] A Meta-Analysis on Clinical Outcomes of Ceftolozane versus Piperacillin in Combination with Tazobactam in Patients with Complicated Urinary Tract Infections
    Saeed, Muhammad Waqas
    Gillani, Syed Wasif
    Mahmood, Rana Kamran
    Vippadapu, Prasanna
    Hussain, Mian Waqar
    Rathore, Hassaan Anwer
    BIOMED RESEARCH INTERNATIONAL, 2022, 2022
  • [48] Ceftolozane/tazobactam dose regimens in severely/morbidly obese patients with complicated intra-abdominal infection or complicated urinary tract infection
    Xiao, Alan J.
    Huntington, Jennifer A.
    Long, Jianmin
    Caro, Luzelena
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2018, 52 (03) : 324 - 330
  • [49] Safety and Efficacy of Ceftolozane/Tazobactam Versus Meropenem in Neonates and Children With Complicated Urinary Tract Infection, Including Pyelonephritis: A Phase 2, Randomized Clinical Trial
    Roilides, Emmanuel
    Ashouri, Negar
    Bradley, John S.
    Johnson, Matthew G.
    Lonchar, Julia
    Su, Feng-Hsiu
    Huntington, Jennifer A.
    Popejoy, Myra W.
    Bensaci, Mekki
    De Anda, Carisa
    Rhee, Elizabeth G.
    Bruno, Christopher J.
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2023, 42 (04) : 292 - 298
  • [50] Analysis of patients with diabetes and complicated intra-abdominal infection or complicated urinary tract infection in phase 3 trials of ceftolozane/tazobactam
    Myra W. Popejoy
    Jianmin Long
    Jennifer A. Huntington
    BMC Infectious Diseases, 17
12345